Emergent BioSolutions raised its revenue guidance and dropped a going concern warning. Its CEO is billing this next chapter ...

My name is Chris, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q3 2024 ...

Emergent BioSolutions (EBS) announced that brincidofovir will be included in a clinical trial conducted and sponsored by Panther, under the ...

Emergent Biosolutions (EBS) stock rose 14% post-market after the company raised the lower end of its revenue guidance range ...

PANTHER to conduct clinical trial under the leadership of Africa Centres for Disease Control and PreventionGAITHERSBURG, Md., Nov. 06, 2024 ...

Concurrently, Emergent BioSolutions announced that brincidofovir (brand name Tembexa for smallpox treatment) will be included ...

Shares of Emergent Biosolutions climbed after the company reported an increase in revenue and swung to a profit in the third quarter. The stock was up 28% to $11.81 in Thursday afternoon trading.

The trial will be conducted in the Democratic Republic of the Congo in partnership with Emergent BioSolutions.

Nov. 06, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that brincidofovir (brand name TEMBEXA®) will be included in a clinical trial conducted and sponsored by ...

Emergent BioSolutions' Q3 earnings report drives 20% surge in share price, reflecting market optimism. See why award a ...

On a per-share basis, the Gaithersburg, Maryland-based company said it had profit of $2.06. Earnings, adjusted for non-recurring gains, were $1.37 per share. The biopharmaceutical company posted ...

Emergent BioSolutions has a 1-year low of $1.42 and a 1-year high of $15.10. The firm has a market capitalization of $483.07 million, a P/E ratio of -0.81 and a beta of 1.59.